ArticleSage open pediatrics
The Effect of Intravesical Injection of Botulinum Toxin A (BTX-A) on Quality of Life of Pediatrics Diagnosed With Overactive Bladder: A Quasi-Experimental Study.
Article in Sage open pediatrics. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: To investigate the effectiveness of Botulinum Toxin A (BTX-A) intravesical injections in improving quality of life (QoL) among pediatric patients. Introduction: Overactive bladder (OAB) in children impacts their QoL. Current treatments often have limitations, necessitating the exploration of alternative therapies. Methods: A quasi-experimental design was conducted in four Jordanian hospitals, with participants being parents of pediatric OAB patients aged 5 to 18 years. Statistical analysis was utilized for data analysis. Results: Results showed that BTX-A injections significantly improved QoL scores for pediatric OAB patients, with marked reductions in symptoms and enhanced well-being in the intervention group. Key demographic factors like household income and age at symptom onset were linked to QoL outcomes, and pre-treatment QoL varied by healthcare provider type. Conclusion: This study highlights BTX-A as a promising therapeutic and advocates for its broader adoption in pediatric urology to enhance the well-being and daily functioning of children with OAB.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.